Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia
Open Access
- 21 July 2010
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 38 (5) , 357-362
Abstract
Background Published guidelines for the treatment of healthcare-associated pneumonia (HCAP) recommend initial broad-spectrum antibiotics with appropriate de-escalation based on culture results. Guideline recommendations are based on data from intubated patients, in whom cultures are easily obtained. The approach to antibiotic de-escalation for culture-negative patients has not been addressed. Consequently, there are no published reports that describe the current standard of practice. Patients and methods All patients admitted to a university hospital with a diagnosis of HCAP, as defined by use of a pneumonia orderset, were identified retrospectively over a 2-year period. Antibiotics prescribed on admission, during hospital stay, and on discharge were recorded. De-escalation was defined as a change in the initial antibiotic therapy from broad- to narrow-spectrum coverage within 14 days of the initial prescription. The Pneumonia Severity Index was used for risk-adjustment. Results A total of 102 patients were included in the analysis; of these, 72% (n = 73) were culture-negative. There were more males in the culture-negative than culture-positive group; otherwise, baseline characteristics were similar. Antibiotic therapy was de-escalated in 75% of the culture-negative group and 77% of the culture-positive group (p = 1.00). Culture-negative patients were de-escalated approximately 1 day earlier than culture-positive patients (3.93 vs. 5.04 days, p = 0.03). Culture-negative patients who were de-escalated had a shorter length of hospitalization, lower hospital costs, and lower mortality rates. In 70% of the culture-negative patients, a respiratory fluoroquinolone was chosen for de-escalation. Conclusion In this single-center study, most of the patients with culture-negative HCAP were safely de-escalated to a respiratory fluoroquinolone.Keywords
This publication has 16 references indexed in Scilit:
- Outcomes of Patients Hospitalized With Community-Acquired, Health Care–Associated, and Hospital-Acquired PneumoniaAnnals of Internal Medicine, 2009
- Antimicrobial Therapy Escalation and Hospital Mortality Among Patients With Health-Care-Associated PneumoniaChest, 2008
- Health Care–Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomes—Proceedings of the HCAP SummitClinical Infectious Diseases, 2008
- Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center ExperienceAntimicrobial Agents and Chemotherapy, 2007
- Antibiotic Therapy and 48-Hour Mortality for Patients with PneumoniaThe American Journal of Medicine, 2006
- Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired PneumoniaThe American Journal of Medicine, 2006
- Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Prospective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Community‐Acquired Pneumonia Requiring HospitalizationClinical Infectious Diseases, 2000
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997
- Clinical Utility of Blood Cultures in Adult Patients with Community-Acquired Pneumonia Without Defined Underlying RisksChest, 1995